NDAORALFOR SUSPENSIONPriority Review
Approved
Dec 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
EMEND (aprepitant) by Merck & Co. is neurokinin 1 antagonists [moa]. First approved in 2015.
Drug data last refreshed 3h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMEND (aprepitant) is a small-molecule neurokinin-1 receptor antagonist approved in 2015 for prevention of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). It works by blocking substance P signaling in the brain's chemoreceptor trigger zone, making it a foundational antiemetic for cancer and surgical patients. The drug is indicated across multiple cancer types including ovarian, breast, colorectal, and lymphoid malignancies, with off-label use expanding into other conditions.
$62KPart D
LOE Approaching1.3 years to LOEProduct is in late-stage lifecycle with patent expiry in 2027; commercial teams should expect portfolio transition planning and defensive market strategies within 1–2 years.
Mechanism of Action
Neurokinin 1 Antagonists
Pharmacologic Class:
Substance P/Neurokinin-1 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Started Feb 2024
518 enrolled
Postoperative Nausea and Vomiting
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Started Jul 2020
27 enrolled
COVID-19
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Started Sep 2019
103 enrolled
Chemotherapy-induced Nausea and Vomiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Started Nov 2018
690 enrolled
Malignant Neoplasm
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
Started Oct 2016
300 enrolled
Chemotherapy-induced Nausea and Vomiting
Worked on EMEND at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.